N,N-Dimethyl-N'-prop-2-yn-1-ylurea | 643083-82-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: N,N-Dimethyl-N'-prop-2-yn-1-ylurea
• 英文别名: 1,1-Dimethyl-3-(prop-2-yn-1-yl)urea；1,1-dimethyl-3-prop-2-ynylurea
• CAS: 643083-82-3
• 化学式: C₆H₁₀N₂O
• mdl: MFCD19159724
• 分子量: 126.158
• InChiKey: NABKXCLVIQJWTD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  N,N-Dimethyl-N'-prop-2-yn-1-ylurea 在 chloro(1,5-cyclooctadiene)rhodium(I) dimer 、 1,1'-bis(diphenylphosphino)ferrocene 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以67%的产率得到C₁₂H₂₀N₄O₂
  参考文献：
  名称：

  铑催化的炔烃头尾二聚和随后的金催化环化反应合成三取代的吡咯

  摘要：

  Abstractmagnified imageDimerization of N‐protected propargylic amines in a rather rare head‐to‐tail mode has been achieved under mild conditions with high selectivity using rhodium catalysts. The N‐protecting group could be a sulfonyl, carbamate, or carbonyl functionality and (cyclooctadiene)rhodium chloride dimer/1,1′‐bis(diphenylphosphino)ferrocene {[Rh(COD)Cl]2/dppf} as well as tris(triphenylphosphine)rhodium chloride [Rh(PPh3)3Cl] proved to be active catalysts. In addition, these functionalized gem‐enynes subsequently undergo selective gold(III)‐catalyzed intramolecular hydroamination to give trisubstituted pyrroles under mild conditions.

  DOI：

  10.1002/adsc.200800735
• 作为产物：
  描述：

  炔丙胺 、 二甲氨基甲酰氯 在 2-二甲氨基吡啶 作用下， 以 吡啶 为溶剂， 生成 N,N-Dimethyl-N'-prop-2-yn-1-ylurea
  参考文献：
  名称：

  NPC1L1 (NPC3) and methods of identifying ligands thereof

  摘要：

  本发明提供了人类、大鼠和小鼠NPCIL1多肽以及编码该多肽的多核苷酸。提供了检测结合到NPC1L1并阻断肠道胆固醇吸收的配体的方法。还包括一种利用从毛细血管膜制备物中得到的膜来识别结合到NPCILI的配体的方法。结合到NPCILI的化合物可用于抑制受试者的肠道胆固醇吸收。

  公开号：

  US07901893B2

文献信息

• [EN] QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DERIVES DE QUINAZOLINE UTILISES DANS LE TRAITEMENT DU CANCER
  申请人：ASTRAZENECA AB

  公开号：WO2004004732A1

  公开（公告）日：2004-01-15

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R1, n, R3,Z2 and R14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  这项发明涉及式（I）的喹唑啉衍生物，其中Z、m、R1、n、R3、Z2和R14中的每一个具有在描述中先前定义的任何含义；它们的制备方法，含有它们的药物组合物以及它们在制造用作抗侵袭或抗增殖剂的药物时在固体肿瘤疾病的控制和/或治疗中的用途。
• Anti-hypercholesterolemic compounds
  申请人：DeVita J. Robert

  公开号：US20070078098A1

  公开（公告）日：2007-04-05

  This invention provides cholesterol absorption inhibitors of Formula I: and the pharmaceutically acceptable salts and esters thereof. The compounds are useful for lowering plasma cholesterol levels, particularly LDL cholesterol, and for treating and preventing atherosclerosis and atherosclerotic disease events.

  这项发明提供了化学式I的胆固醇吸收抑制剂及其药用盐和酯。这些化合物对降低血浆胆固醇水平，特别是LDL胆固醇，以及治疗和预防动脉粥样硬化和动脉粥样硬化疾病事件具有用处。
• NPC1L1 (NPC3) and methods of identifying ligands thereof
  申请人：Merck Sharp & Dohme Corp.

  公开号：US07901893B2

  公开（公告）日：2011-03-08

  The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject.

  本发明提供了人类、大鼠和小鼠NPCIL1多肽以及编码该多肽的多核苷酸。提供了检测结合到NPC1L1并阻断肠道胆固醇吸收的配体的方法。还包括一种利用从毛细血管膜制备物中得到的膜来识别结合到NPCILI的配体的方法。结合到NPCILI的化合物可用于抑制受试者的肠道胆固醇吸收。
• Quinzoline derivatives for use in the treatment of cancer
  申请人：Hennequin Francois Andre Laurent

  公开号：US20050250797A1

  公开（公告）日：2005-11-10

  The invention concerns quinazoline derivatives of Formula (I) wherein each of Z, m, R 1 , n, R 3 ,Z 2 and R 14 have any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use as an anti-invasive or anti-proliferative agent in the containment and/or treatment of solid tumour disease.

  本发明涉及公式（I）的喹唑啉衍生物，其中Z，m，R1，n，R3，Z2和R14中的每一个都具有本说明书中定义的任何含义；它们的制备过程，含有它们的制药组合物以及它们在制造用于抗侵袭或抗增殖剂的药物时，在包含和/或治疗实体肿瘤疾病方面的用途。
• Npcil1 (Npc3) And Methods Of Identifying Ligands Thereof
  申请人：Garcia-Calvo Maria Margarita

  公开号：US20100009461A1

  公开（公告）日：2010-01-14

  The present invention provides human, rat and mouse NPCIL1 polypeptides and polynucleotides encoding the polypeptides. Methods for detecting ligands which bind to NPC1L1 and block intestinal cholesterol absorption are provided. Also included is a method of identifying ligands which bind to NPCILI using membranes derived from brush border membrane preparations. Compounds that bind to NPCILI can be used for inhibiting intestinal cholesterol absorption in a subject.

  本发明提供人、大鼠和小鼠NPCIL1多肽和编码该多肽的多核苷酸。提供检测与NPC1L1结合并阻止肠道胆固醇吸收的配体的方法。还包括使用来自刷状缘膜制备的膜鉴定与NPCILI结合的配体的方法。与NPCILI结合的化合物可用于抑制受试者的肠道胆固醇吸收。